Mereo BioPharma investors sue over alleged Phase 3 trial failures, material omissions.

Mereo BioPharma Group plc (NASDAQ:MREO) shareholders filed a lawsuit alleging they were misled about the challenges facing the setrusumab program. Key events include the announcement of positive Phase 2 data, full enrollment completion, and the failure of both Phase 3 trials. Shareholders claim they were kept in the dark about fundamental challenges, and contact information is provided for those who suffered losses.